Payment overview · 2025
General Payments
$825.36
42 reported records · 18 companies
Healthcare provider profile · identity verified
Jay William Floyd, MD
Allopathic & Osteopathic Physicians|Family Medicine · BRUNSWICK, GA · NPI 1861460313
Verified facts
What the public records show
CMS Open Payments records show Jay William Floyd, MD received $825.36 in general payments during 2025 across 42 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 14.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $119.72 | 14.5% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $92.92 | 11.3% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $71.21 | 8.6% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $68.00 | 8.2% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $52.96 | 6.4% | 3 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $52.23 | 6.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.35 | 6.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.74 | 5.8% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $41.82 | 5.1% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $35.66 | 4.3% | 2 | 2025 |
| Saluda Medical Americas, Inc. | Unresolved — no canonical attribution shown | $34.72 | 4.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.84 | 4.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.60 | 2.9% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $22.41 | 2.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $22.33 | 2.7% | 1 | 2025 |
| BIOTRONIK NRO, Inc. | Unresolved — no canonical attribution shown | $22.32 | 2.7% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $20.04 | 2.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $13.49 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $825.36 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $119.72 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $71.21 | 4 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $68.00 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $53.93 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $52.96 | 3 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $52.23 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $41.82 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $38.99 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $35.66 | 2 | 2025 |
Source payment records
|
|||||
| Evoke Normalized: evoke |
Device | Saluda Medical Americas, Inc. | $34.72 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $33.84 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $33.84 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.99 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.99 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $32.62 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.60 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.60 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $22.33 | 1 | 2025 |
Source payment records
|
|||||
| Prospera Normalized: prospera |
Device | BIOTRONIK NRO, Inc. | $22.32 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 40 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 35 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
20 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
154 | 42 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
35 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
40 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
75 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 568 | 184 |
| Atorvastatin Calcium | Atorvastatin Calcium | 380 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 343 | 101 |
| Losartan Potassium | Losartan Potassium | 316 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 309 | 91 |
| Omeprazole | Omeprazole | 267 | 78 |
| Metformin Hcl | Metformin Hcl | 218 | 70 |
| Gabapentin | Gabapentin | 203 | 70 |
| Lisinopril | Lisinopril | 182 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 174 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 157 | 54 |
| Farxiga | Dapagliflozin Propanediol | 154 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 154 | 46 |
| Potassium Chloride | Potassium Chloride | 150 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 140 | 42 |
| Furosemide | Furosemide | 134 | 49 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 130 | 48 |
| Ozempic | Semaglutide | 125 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 35 |
| Montelukast Sodium | Montelukast Sodium | 102 | 26 |
| Glimepiride | Glimepiride | 95 | 31 |
| Famotidine | Famotidine | 94 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 87 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 86 | 19 |
| Trazodone Hcl | Trazodone Hcl | 83 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 26 |
| Eliquis | Apixaban | 75 | 22 |
| Simvastatin | Simvastatin | 71 | 23 |
| Allopurinol | Allopurinol | 70 | 23 |
| Trulicity | Dulaglutide | 70 | 13 |
| Carvedilol | Carvedilol | 68 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 21 |
| Spironolactone | Spironolactone | 66 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 16 |
| Indapamide | Indapamide | 56 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 49 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 25 |
| Valsartan | Valsartan | 52 | 13 |
| Prednisone | Prednisone | 51 | 42 |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | 17 |
| Sertraline Hcl | Sertraline Hcl | 48 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 13 |
| Ezetimibe | Ezetimibe | 45 | 17 |
| Pregabalin | Pregabalin | 44 | 14 |
| Buspirone Hcl | Buspirone Hcl | 43 | 19 |
| Valacyclovir | Valacyclovir Hcl | 42 | 12 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 40 | 39 |
| Bupropion Xl | Bupropion Hcl | 40 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 11 |
| Jardiance | Empagliflozin | 39 | 12 |
| Meloxicam | Meloxicam | 37 | 19 |
| Atenolol | Atenolol | 36 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 35 | 29 |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 30 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 29 | 11 |
| Varenicline Tartrate | Varenicline Tartrate | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | 11 |
| Methylprednisolone | Methylprednisolone | 28 | 28 |
| Estradiol | Estradiol | 27 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 27 | suppressed |
| Levemir Flexpen | Insulin Detemir | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Klor-Con M20 | Potassium Chloride | 25 | 13 |
| Meclizine Hcl | Meclizine Hcl | 25 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 24 | 22 |
| Fluconazole | Fluconazole | 24 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Prolia | Denosumab | 20 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 15 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Captopril | Captopril | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $825.36 · 42 records | Bayer Healthcare Pharmaceuticals Inc. | ABRYSVO, AIRSUPRA, AREXVY, AUSTEDO XR, CAPLYTA, COMIRNATY, Cologuard Collection Kit, EVENITY, Evoke, FREESTYLE LIBRE, General - Pain Management, IBSRELA, INSPIRE, KRYSTEXXA, Kerendia, NURTEC ODT, Omnipod, PREVNAR 20, Prospera, QULIPTA, SHINGRIX, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, XIFAXAN, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error